A novel quantitative model based on gross tumor volume corresponding to anatomical distribution measured with multidetector computed tomography to determine the resectability of non‑distant metastatic esophageal squamous cell carcinoma

Gao,Dan; Ou,Jing; Tan,Bang-Guo; Yu,Zi-Yi; Li,Ke-Ying; Li,Rui; Zhang,Xiao-Ming; Chen,Tian-Wu; Zhou,Hai-Ying

doi:10.3892/ol.2023.14072

A novel quantitative model based on gross tumor volume corresponding to anatomical distribution measured with multidetector computed tomography to determine the resectability of non‑distant metastatic esophageal squamous cell carcinoma

Authors:
- Dan Gao
- Jing Ou
- Bang-Guo Tan
- Zi-Yi Yu
- Ke-Ying Li
- Rui Li
- Xiao-Ming Zhang
- Tian-Wu Chen
- Hai-Ying Zhou
View Affiliations

Affiliations: Medical Imaging Key Laboratory of Sichuan Province, Department of Radiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, Department of Radiology, Panzhihua Central Hospital, Panzhihua, Sichuan 617067, P.R. China
Published online on: September 26, 2023 https://doi.org/10.3892/ol.2023.14072
Article Number: 485
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It is important to accurately determine the resectability of thoracic esophageal squamous cell carcinoma (ESCC) for treatment decision‑making. Previous studies have revealed that the CT‑derived gross tumor volume (GTV) is associated with the staging of ESCC. The present study aimed to explore whether the anatomical distribution‑based GTV of non‑distant metastatic thoracic ESCC measured using multidetector computed tomography (MDCT) could quantitatively determine the resectability. For this purpose, 473 consecutive patients with biopsy‑confirmed non‑distant metastatic thoracic ESCC who underwent contrast‑enhanced CT were randomly divided into a training cohort (TC; 376 patients) and validation cohort (VC; 97 patients). GTV was retrospectively measured using MDCT. Univariate and multivariate analyses were performed to identify the determinants of the resectability of ESCC in the TC. Receiver operating characteristic (ROC) analysis was performed to clarify whether anatomical distribution‑based GTV could help quantitatively determinate resectability. Unweighted Cohen's Kappa tests in VC were used to assess the performance of the previous models. Univariate analysis demonstrated that sex, anatomic distribution, cT stage, cN stage and GTV were related to the resectability of ESCC in the TC (all P<0.05). Multivariate analysis revealed that GTV [P<0.001; odds ratio (OR) 1.158] and anatomic distribution (P=0.027; OR, 1.924) were independent determinants of resectability. ROC analysis revealed that the GTV cut‑offs for the determination of the resectability of the upper, middle and lower thoracic portions were 23.57, 22.89 and 22.58 cm3, respectively, with areas under the ROC curves of >0.9. Unweighted Cohen's Kappa tests revealed an excellent performance of the ROC models in the upper, middle and lower thoracic portions with Cohen k‑values of 0.913, 0.879 and 0.871, respectively. On the whole, the present study demonstrated that GTV and the anatomic distribution of non‑distant metastatic thoracic ESCC may be independent determinants of resectability, and anatomical distribution‑based GTV can effectively be used to quantitatively determine resectability.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P and Cunningham D: Oesophageal cancer. Nat Rev Dis Primers. 3:170482017. View Article : Google Scholar : PubMed/NCBI
3	Kato H and Nakajima M: Treatments for esophageal cancer: A review. Gen Thorac Cardiovasc Surg. 61:330–335. 2013. View Article : Google Scholar : PubMed/NCBI
4	Jiao R, Luo H, Xu W and Ge H: Immune checkpoint inhibitors in esophageal squamous cell carcinoma: Progress and opportunities. Onco Targets Ther. 12:6023–6032. 2019. View Article : Google Scholar : PubMed/NCBI
5	Ma X, Zhao W, Li B, Yu Y, Ma Y, Thomas M and Zhang Y, Xiang J and Zhang Y: Neoadjuvant immune checkpoint inhibitors plus chemotherapy in locally advanced esophageal squamous cell carcinoma: Perioperative and survival outcomes. Front Oncol. 12:8108982022. View Article : Google Scholar : PubMed/NCBI
6	Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, et al: Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 17:855–883. 2019. View Article : Google Scholar : PubMed/NCBI
7	Giganti F, Ambrosi A, Petrone MC, Canevari C, Chiari D, Salerno A, Arcidiacono PG, Nicoletti R, Albarello L, Mazza E, et al: Prospective comparison of MR with diffusion-weighted imaging, endoscopic ultrasound, MDCT and positron emission tomography-CT in the pre-operative staging of oesophageal cancer: Results from a pilot study. Br J Radiol. 89:201600872016. View Article : Google Scholar : PubMed/NCBI
8	Ou J, Li R, Zeng R, Wu CQ, Chen Y, Chen TW, Zhang XM, Wu L, Jiang Y, Yang JQ, et al: CT radiomic features for predicting resectability of oesophageal squamous cell carcinoma as given by feature analysis: A case control study. Cancer Imaging. 19:662019. View Article : Google Scholar : PubMed/NCBI
9	Umeoka S, Koyama T, Togashi K, Saga T, Watanabe G, Shimada Y and Imamura M: Esophageal cancer: Evaluation with triple-phase dynamic CT-initial experience. Radiology. 239:777–783. 2006. View Article : Google Scholar : PubMed/NCBI
10	Kuriakose MA, Loree TR, Hicks WL, Welch JJ, Wang H and DeLacure MD: Tumour volume estimated by computed tomography as a predictive factor in carcinoma of the tongue. Br J Oral Maxillofac Surg. 38:460–465. 2000. View Article : Google Scholar : PubMed/NCBI
11	Li H, Chen TW, Li ZL, Zhang XM, Chen XL, Wang LY, Zhou L, Li R, Li CP and Huang XH: Tumour size of resectable oesophageal squamous cell carcinoma measured with multidetector computed tomography for predicting regional lymph node metastasis and N stage. Eur Radiol. 22:2487–2493. 2012. View Article : Google Scholar : PubMed/NCBI
12	Li H, Chen TW, Zhang XM, Li ZL, Chen XL, Tang HJ, Huang XH, Chen N, Yang Q and Hu JN: Computed tomography scan as a tool to predict tumor T category in resectable esophageal squamous cell carcinoma. Ann Thorac Surg. 95:1749–1755. 2013. View Article : Google Scholar : PubMed/NCBI
13	Moss AA, Schnyder P, Thoeni RF and Margulis AR: Esophageal carcinoma: Pretherapy staging by computed tomography. AJR Am J Roentgenol. 136:1051–1056. 1981. View Article : Google Scholar : PubMed/NCBI
14	Koo TK and Li MY: A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 15:155–163. 2016. View Article : Google Scholar : PubMed/NCBI
15	Wu YP, Tang S, Tan BG, Yang LQ, Lu FL, Chen TW, Ou J, Zhang XM, Gao D, Li KY, et al: Tumor stage-based gross tumor volume of resectable esophageal squamous cell carcinoma measured on CT: Association with early recurrence after esophagectomy. Front Oncol. 11:7537972021. View Article : Google Scholar : PubMed/NCBI
16	Qiao J, Qin J, Xing D, Li S and Wu D: Diagnosis of retrolingual obstruction during drug-induced sleep endoscopy versus polysomnography with nasopharyngeal tube in patients with obstructive sleep apnea. Ann Otol Rhinol Laryngol. 130:1285–1291. 2021. View Article : Google Scholar : PubMed/NCBI
17	Rice TW, Ishwaran H, Blackstone EH, Hofstetter WL, Kelsen DP and Apperson-Hansen C; Worldwide Esophageal Cancer Collaboration Investigators, : Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 29:913–919. 2016. View Article : Google Scholar : PubMed/NCBI
18	Panebianco V, Grazhdani H, Iafrate F, Petroni M, Anzidei M, Laghi A and Passariello R: 3D CT protocol in the assessment of the esophageal neoplastic lesions: Can it improve TNM staging? Eur Radiol. 16:414–421. 2006. View Article : Google Scholar : PubMed/NCBI
19	Shi H, Zhang K, Niu ZX, Wang WP, Gao Q and Chen LQ: Does tumour location influence postoperative long-term survival in patients with oesophageal squamous cell carcinoma? Eur J Cardiothorac Surg. 48:266–272. 2015. View Article : Google Scholar : PubMed/NCBI
20	Rice TW, Rusch VW, Apperson-Hansen C, Allen S, Chen LQ, Hunter JG, Kesler KA, Law S, Lerut TE, Reed CE, et al: Worldwide esophageal cancer collaboration. Dis Esophagus. 22:1–8. 2009. View Article : Google Scholar : PubMed/NCBI
21	Kato H, Tachimori Y, Watanabe H, Yamaguchi H, Ishikawa T and Kagami Y: Thoracic esophageal carcinoma above the carina: A more formidable adversary? J Surg Oncol. 65:28–33. 1997. View Article : Google Scholar : PubMed/NCBI
22	Kuwano H, Nishimura Y, Oyama T, Kato H, Kitagawa Y, Kusano M, Shimada H, Takiuchi H, Toh Y, Doki Y, et al: Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan esophageal society. Esophagus. 12:1–30. 2015. View Article : Google Scholar : PubMed/NCBI
23	Kim S, Han K, Seo N, Kim HJ, Kim MJ, Koom WS, Ahn JB and Lim JS: T2-weighted signal intensity-selected volumetry for prediction of pathological complete response after preoperative chemoradiotherapy in locally advanced rectal cancer. Eur Radiol. 28:5231–5240. 2018. View Article : Google Scholar : PubMed/NCBI
24	Zhao Q, Wan L, Zou S, Zhang C E T, Yang Y, Ye F, Zhao X, Ouyang H and Zhang H: Prognostic risk factors and survival models for T3 locally advanced rectal cancer: What can we learn from the baseline MRI? Eur Radiol. 31:4739–4750. 2021. View Article : Google Scholar : PubMed/NCBI